Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase GERMANTOWN, Md., Dec. 27, 2022 /PRNewswire/ — Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission …
Trending at Lumira Ventures
FDA Grants Fast Track to Edesa Biotech’s ARDS Drug Candidate
Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory …
HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors
Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO, Erica Rogers, to its Board of Directors HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85 …
World Antimicrobial Awareness Week 2022
Antimicrobial resistance (AMR) occurs when microbes (bacteria, viruses, fungi and parasites) change over time and evolve mechanisms that protect them from the effects of antimicrobials. This process results in microbes no longer responding to medications, making the treatment of infections …
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chief Medical Officer
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. “We are pleased to welcome Dmitri to Fusion’s leadership team at …
Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer
Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing a fundamental mechanism in cancer-driving oncogenes October 19, 2022 – PIC Therapeutics, Inc., …
World Mental Health Day 2022
In 2021, Lumira Ventures and Angelini Pharma launched the Angelini Lumira Biosciences Fund (ALBF) to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. Through our …
DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging
TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging. The …
A Look Around The Corner For Life Sciences: Nikhil Thatte Speaks at the 2022 Atlantic Venture Forum
Tomorrow, Tuesday, September 13th, 2022 at 3 pm ET, Lumira Ventures Principal, Nikhil Thatte will be presenting as the keynote speaker for the 2022 Atlantic Venture Forum (AVF). The AVF is the largest annual convergence of industry leaders, access to …
Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations
GERMANTOWN, Md., Sept. 8, 2022 /PRNewswire/ — Deka Biosciences (“Deka”), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) …
2022 Lumira Venture Innovation Program (VIP): Fall Cohort Applications Open
The Venture Innovation Program is a 6-12 month program for Ph.D., MBA, and MD students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the future of life sciences innovation …
Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced completion of subject enrollment in the Company’s ongoing STS101 SUMMIT pivotal …
Summer Office Hour Registration is Open!
Lumira Ventures is excited to present our 2022 Office Hours beginning this August! Every Wednesday from 4:00 – 5:00 PM ET, Associates Baye Galligan and Suman Rao will be available to chat with members of our community and answer any …
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4 targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggregate of 50,925,365 shares …
Expanding Pipeline Leads to Name Change – LQT Therapeutics Now Thryv Therapeutics
New Name Emphasizes Relentless Pursuit of an Expanded and Rare Disease Portfolio Oncology Programs added to existing Long QT Syndrome Program (“LQTS”) Additional US$15M Financing Provides Fuel for Proof-of-Concept in LQTS LAVAL, Québec, Canada | 11 July 2022 | Thryv …